IGFBP7 and melanoma: Treatment with recombinant exogenous IGFBP7 human melanoma cell lines carrying mutated BRAF can induce cell senescence and apoptosis [115,116], and systemically administrated in xenograft mouse models counteract melanoma growth [115,117].